EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

被引:5
|
作者
Chalela, Roberto [1 ,2 ,3 ,4 ]
Bellosillo, Beatriz [2 ,3 ,5 ]
Curull, Victor [1 ,2 ,4 ,6 ]
Longaron, Raquel [5 ]
Pascual-Guardia, Sergi [1 ,2 ,3 ,4 ]
Badenes-Bonet, Diana [1 ,2 ,3 ]
Arriola, Edurne [2 ,7 ]
Sanchez-Font, Albert [1 ,2 ,6 ]
Pijuan, Lara [5 ]
Gea, Joaquim [1 ,2 ,3 ,4 ]
机构
[1] Hosp del Mar, Resp Med Dept, Barcelona 08003, Spain
[2] Hosp del Mar Med Res Inst IMIM, Barcelona 08003, Spain
[3] Univ Pompeu Fabra, Sch Hlth & Life Sci, Barcelona 08003, Spain
[4] Inst Salud Carlos III, CIBER Enfermedades Resp CibeRes, Madrid 28029, Spain
[5] Hosp del Mar, Dept Pathol, Barcelona 08003, Spain
[6] Univ Autonoma Barcelona, Barcelona 08003, Spain
[7] Hosp del Mar, Dept Oncol, Barcelona 08003, Spain
关键词
Adenocarcinoma; Mutations; EGFR; KRAS; Prognosis; CANCER; SURVIVAL; CLASSIFICATION; ASSOCIATION;
D O I
10.3390/jcm8040529
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Long-term prognosis of patients with cancer-related mutations in non-tumoral lung
    Chalela, Roberto
    Khilzi, Karys
    Gea, Joaquin
    Sanchez-Font, Albert
    Pijuan, Lara
    Gregorio Gonzalez-Garcia, Jose
    Badenes-Bonet, Diana
    Bellosillo, Beatriz
    Curull, Victor
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [2] KRAS and EGFR mutations coexisting in lung adenocarcinoma
    Vitor Sousa
    Ana Alarcão
    Patricia Couceiro
    Maria R Silva
    Maria J d’Aguiar
    Lia Teixeira
    Lina Carvalho
    [J]. BMC Proceedings, 4 (Suppl 2)
  • [3] Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma
    Johnson, M. L.
    Sima, C.
    Paik, P. K.
    Janjigian, Y. Y.
    Pao, W.
    Kris, M. G.
    Ladanyi, M.
    Riely, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
    Chalela, Roberto
    Gonzalez-Garcia, Jose Gregorio
    Khilzi, Karys
    Curull, Victor
    Sanchez-Font, Albert
    Longaron, Raquel
    Rodrigo-Calvo, Maria Teresa
    Martin-Ontiyuelo, Clara
    Gea, Joaquim
    Bellosillo, Beatriz
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [5] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Luka Brcic
    Marko Jakopovic
    Marija Misic
    Fran Seiwerth
    Izidor Kern
    Silvana Smojver-Jezek
    Franz Quehenberger
    Miroslav Samarzija
    Sven Seiwerth
    [J]. Diagnostic Pathology, 11
  • [6] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Brcic, Luka
    Jakopovic, Marko
    Misic, Marija
    Seiwerth, Fran
    Kern, Izidor
    Smojver-Jezek, Silvana
    Quehenberger, Franz
    Samarzija, Miroslav
    Seiwerth, Sven
    [J]. DIAGNOSTIC PATHOLOGY, 2016, 11 : 1
  • [7] Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients
    Taus, Alvaro
    Camacho, Laura
    Hernandez, Ainhoa
    Piquer, Gabriel
    Lopez, Eva
    Dalmases, Alba
    Casadevall, David
    Pijuan, Lara
    Hardy, Max
    Longaron, Raquel
    Rocha, Pedro
    Zafra, Arnau
    Albanell, Joan
    Bellosillo, Beatriz
    Arriola, Edurne
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S511 - S511
  • [8] Lung surgery for non-tumoral disease
    Riquet, M.
    Mordant, P.
    [J]. REVUE DE PNEUMOLOGIE CLINIQUE, 2012, 68 (02) : 65 - 66
  • [9] Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
    Zhou, Xiuzhi
    Cai, Li
    Liu, Junjie
    Hua, Xiaomin
    Zhang, Ying
    Zhao, Huilin
    Wang, Bin
    Li, Boqing
    Gai, Pengzhou
    [J]. ONCOLOGY LETTERS, 2018, 16 (01) : 362 - 370
  • [10] The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma
    Kitamura, Jiro
    Tapias, Luis
    Mathisen, Douglas
    Lanuti, Michael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S620 - S621